227 related articles for article (PubMed ID: 19820441)
1. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy.
Dudley-Brown S; Nag A; Cullinan C; Ayers M; Hass S; Panjabi S
Gastroenterol Nurs; 2009; 32(5):327-39. PubMed ID: 19820441
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.
Feagan BG; Sandborn WJ; Hass S; Niecko T; White J
Am J Gastroenterol; 2007 Dec; 102(12):2737-46. PubMed ID: 18042106
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
[TBL] [Abstract][Full Text] [Related]
6. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S;
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
[TBL] [Abstract][Full Text] [Related]
8. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.
Feagan BG; Coteur G; Tan S; Keininger DL; Schreiber S
Am J Gastroenterol; 2009 Aug; 104(8):1976-83. PubMed ID: 19471252
[TBL] [Abstract][Full Text] [Related]
9. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study.
Omer B; Krebs S; Omer H; Noor TO
Phytomedicine; 2007 Feb; 14(2-3):87-95. PubMed ID: 17240130
[TBL] [Abstract][Full Text] [Related]
10. The effects of infliximab maintenance therapy on health-related quality of life.
Feagan BG; Yan S; Bala M; Bao W; Lichtenstein GR
Am J Gastroenterol; 2003 Oct; 98(10):2232-8. PubMed ID: 14572573
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Inflammatory Bowel Disease Questionnaire in Swedish patients with Crohn's disease.
Stjernman H; Grännö C; Bodemar G; Järnerot G; Ockander L; Tysk C; Blomberg B; Almer S; Ström M; Hjortswang H
Scand J Gastroenterol; 2006 Aug; 41(8):934-43. PubMed ID: 16803692
[TBL] [Abstract][Full Text] [Related]
12. Impact of surgery for Crohn's disease on health-related quality of life.
Casellas F; López-Vivancos J; Badia X; Vilaseca J; Malagelada JR
Am J Gastroenterol; 2000 Jan; 95(1):177-82. PubMed ID: 10638579
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of natalizumab for formulary consideration.
Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
[TBL] [Abstract][Full Text] [Related]
14. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.
Ng SC; Plamondon S; Gupta A; Burling D; Kamm MA
Aliment Pharmacol Ther; 2009 Oct; 30(7):757-66. PubMed ID: 19575762
[TBL] [Abstract][Full Text] [Related]
15. Low-dose naltrexone therapy improves active Crohn's disease.
Smith JP; Stock H; Bingaman S; Mauger D; Rogosnitzky M; Zagon IS
Am J Gastroenterol; 2007 Apr; 102(4):820-8. PubMed ID: 17222320
[TBL] [Abstract][Full Text] [Related]
16. Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease?
Horváth G; Farkas K; Hollósi R; Nagy F; Szepes Z; Papp M; Palatka K; Miheller P; Lakatos L; Szamosi T; Nyári T; Wittmann T; Molnár T
Scand J Gastroenterol; 2012 Nov; 47(11):1298-303. PubMed ID: 22935014
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.
Allgulander C; Jørgensen T; Wade A; François C; Despiegel N; Auquier P; Toumi M
Curr Med Res Opin; 2007 Oct; 23(10):2543-9. PubMed ID: 17825130
[TBL] [Abstract][Full Text] [Related]
18. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of medically induced remission of Crohn's disease.
Gonvers JJ; Juillerat P; Mottet C; Pittet V; Felley C; Vader JP; Michetti P; Froehlich F
Digestion; 2007; 76(2):116-29. PubMed ID: 18239403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
